Coherus Oncology (CHRS) Net Income towards Common Stockholders (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 84.82% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at $358.9 million (up 452.16% YoY), and the FY2025 full-year result was $351.1 million, up 43.97% from the prior year.
• Net Income towards Common Stockholders slipped to -$1.4 million in Q1 2026, from $8.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $342.6 million in Q2 2025 to a low of -$96.1 million in Q1 2022.
• A 5-year average of $3.8 million and a median of -$9.2 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 124.9% in 2022 and jumped 717.15% in 2025, its largest moves.
• Tracing CHRS's Net Income towards Common Stockholders over 5 years: stood at -$58.9 million in 2022, then sank by 35.3% to -$79.7 million in 2023, then soared by 94.22% to -$4.6 million in 2024, then soared by 289.09% to $8.7 million in 2025, then slumped by 115.99% to -$1.4 million in 2026.
• Business Quant data shows CHRS's Net Income towards Common Stockholders at -$1.4 million in Q1 2026, $8.7 million in Q4 2025, and $9.0 million in Q3 2025.